If this is where you are
Newly diagnosedReports arriving, no plan yetAlready tested elsewhereYou have results you cannot readOn treatment nowYou want to know it is workingOr
Finished treatmentWatching for anything left behindWorried about familyInherited risk, and relativesWanting a second opinionA decision you are unsure aboutDecide
Blueprint CareThe flagship decision report and a dedicated clinical teamSignalOne free question answered on WhatsApp within four hoursNavigationRecords you already have, turned into a clarity timelineDecipherInterpretation of sequencing already done elsewhereTest
Signature, all tiersSolid tumour and blood cancer panels comparedSignature STb33 genes from a blood drawSignature STb O118 genes from a blood drawSignature STb O+523 genes, with TMB and MSISignature STt OProfiling from an existing tissue blockMonitor
SentinelSerial monitoring while treatment is runningSentinel SolidctDNA monitoring for solid tumoursClearMolecular residual disease surveillanceClear SolidTumour-informed surveillanceProtect
HeritageInherited risk, assessed properlyHeritage CoreA broad inherited-risk assessmentHeritage AdhocFocused testing for named relativesCancer DictionaryWhat is discussed in your specific cancerReference
Cancer DictionaryOne structured entry per cancer typeBiomarker LibraryOne page per marker, in plain languagePatient ResourcesGlossary, guides and how to use themWatch, read and ask
Video LibraryShort explainers, captioned and translatedStoriesPatient and clinician experiences, consentedFAQThe questions we are asked mostCancer Dictionary · Thoracic
Mesothelioma is defined by histological subtype and by the loss of specific tumour suppressor genes. Because the characteristic alterations are deletions rather than activating mutations, the therapeutic conversation is about exploiting a loss rather than blocking a gain, and much of it remains investigational.
Also called Malignant pleural mesothelioma, Peritoneal mesothelioma.
Start here
Mesothelioma is characterised by loss of tumour suppressors rather than by gain of a targetable driver, which is why the molecular discussion is about vulnerabilities created by what is missing.
Mesothelioma is defined by histological subtype and by the loss of specific tumour suppressor genes. Because the characteristic alterations are deletions rather than activating mutations, the therapeutic conversation is about exploiting a loss rather than blocking a gain, and much of it remains investigational.
01Before any molecular question
Usually established first: the site (pleural or peritoneal), the histological subtype (epithelioid, sarcomatoid or biphasic), and whether the disease is resectable. Subtype carries substantial weight in the management discussion.
Usually already established
02
The divisions below are not labels. Each one changes what the treatment discussion is actually about.
Epithelioid
The subtype most often considered for aggressive multimodality approaches.
Sarcomatoid
Behaves differently and is generally managed systemically.
Biphasic
Mixed features. The proportion of each component is part of the discussion.
Peritoneal
A distinct site with its own management logic, including locoregional approaches.
03What is discussed
The characteristic findings are losses: BAP1, CDKN2A and NF2. BAP1 loss is also the alteration that raises a germline question. CDKN2A deletion is relevant to cell cycle biology and to research strategies targeting it. MTAP loss, which frequently accompanies CDKN2A deletion, is under study as a therapeutic vulnerability. Mesothelioma is a disease where a negative profiling result is informative rather than disappointing, because it is consistent with the expected biology.
BAP1
Loss is characteristic, supports the diagnosis, and raises a germline question.
CDKN2A
Deletion is common and relevant to cell cycle research strategies.
NF2
Loss is part of the characteristic pattern.
MTAP
Often lost alongside CDKN2A. Under study as a therapeutic vulnerability.
Mesothelin
A surface target relevant to research approaches rather than a genomic marker.
This is not an exhaustive list, and which markers are relevant depends on the individual case. Not every marker listed is assessed in every patient.
04What is tested, and from what
Profiling in mesothelioma is discussed for three reasons: supporting a difficult diagnosis, raising or settling a germline question through BAP1, and trial eligibility. It is less often a route to an approved targeted therapy than in lung adenocarcinoma, and that expectation is worth setting before testing rather than after.
Germline BAP1 alteration defines a recognised tumour predisposition syndrome associated with mesothelioma, uveal melanoma, renal cell carcinoma and certain skin lesions. A somatic BAP1 finding, a young age at diagnosis, or a suggestive family pattern are the usual prompts for raising the germline question formally.
Cancer genetics and hereditary risk05The timing question
Testing that arrives after the decision it was meant to inform has already been made is a common and avoidable problem. This is the sequence in which molecular information tends to become relevant.
06Take these to your team
When a decision is being made
Questions worth raising with a treating team.
At progression, recurrence or resistance
The molecular picture at diagnosis is not always the molecular picture later.
07What shapes eligibility
A high proportion of the therapeutic activity in mesothelioma is in trials. Subtype, prior treatment and specific molecular losses commonly appear in eligibility criteria.
| Term | What it means |
|---|---|
| Tumour suppressor | A gene whose normal job is to restrain growth. Cancer can arise when it is lost rather than when something is gained. |
| Biphasic | Containing both epithelioid and sarcomatoid components. |
| Latency | The long interval, often decades, between asbestos exposure and diagnosis. |
These are the services most often relevant to this cancer. Which of them applies is a clinical question, not an automatic one.
This entry is educational. It describes what is commonly discussed in this cancer, not what should happen for any individual. Which of it applies depends on the specific diagnosis, stage, prior treatment and the person themselves. Nothing here is a recommendation, and no list of biomarkers here is exhaustive. Decisions belong with a treating team who know the whole case.
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal